Articles tagged "Antibodies"

2020 American Transplant Congress
Intimal Arteritis in Association with Microvascular Inflammation Leads to Inferior Graft Survival Regardless DSA
M. Novotny¹, E. Honsova², O. Viklicky¹
¹Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, ²Department of Clinical and Transplant Pathology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
*Purpose: Intimal arteritis belongs between diagnostic criteria of both antibody-mediated rejection (AMR) and T cell-mediated vascular rejection (TCMRV). Patients with intimal arteritis must be assessed…
2020 American Transplant Congress
Antibodies to Vascular Autoantigens Are Associated with Poor Long-Term Survival of Liver Re-Transplant
Q. Xu¹, V. C. McAlister², S. Leckie², A. A. House², A. Zeevi¹
¹Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Multiorgan Transplant Program, London Health Sciences Centre, London, ON, Canada
*Purpose: Autoantibodies, which may be generated in transplantation through the exposure of cryptic antigens, are reported to be detrimental for allograft survival. We have demonstrated…
2020 American Transplant Congress
7-Years Retrospective Cohort of CNI to Belatacept Conversion
A. Morel¹, C. Dudreuilh¹, A. Moktefi², D. Kheav³, D. Mokrani¹, K. El Sakhawi¹, C. Champy⁴, P. Rémy¹, P. Grimbert¹, M. Matignon¹
¹Nephrology, APHP Henri Mondor, Créteil, France, ²Anatomopathology, APHP Henri Mondor, Créteil, France, ³Immunology, APHP Saint Louis, Paris, France, ⁴Urology, APHP Henri Mondor, Créteil, France
*Purpose: Analyze the long-term evolution after calcineurin inhibitors (CNIs) to Belatacept conversion in kidney allograft recipients.*Methods: In this single-center retrospective study, we collected all patients…
2020 American Transplant Congress
The Frequency of De Novo DSA in the Years Following Heart Transplantation
A. Shen, J. Patel, M. Kittleson, D. Chang, E. Kransdorf, D. Geft, K. Nishihara, L. Czer, F. Esmailian, J. A. Kobashigawa
Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
*Purpose: The timing of the development of donor specific antibody (DSA) after heart transplantation is not clear. De novo DSA has been reported to be…
2020 American Transplant Congress
Characterization of Non HLA Antibodies in Kidney Transplant Recipients
S. Rodriguez Ramirez¹, S. Clotet-Freixas¹, C. Mcevoy¹, M. Kotlyar², I. Jurisica², A. Chruscinski¹, A. Konvalinka³
¹Kidney Transplant, Toronto General Hospital Research Institute, Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada, ²Kidney Transplant, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³Kidney Transplant, Department of Medicine, Division of Nephrology, University Health Network, Toronto, ON, Canada
*Purpose: Antibody mediated rejection (AMR) causes more than 60 percent of late graft failures in kidney transplants (KT). Although antiHLA donor specific antibodies are the…
2019 American Transplant Congress
Successful Kidney Transplantation of Highly Sensitized Candidates across Positive Cross Match and Strong Donor-Specific HLA-DP Antibodies without Desensitization
R. Rajalingam¹, D. D. Gae², Z. G. Laszik³, M. M. Tavakol⁴, A. B. Webber⁵, K. Cunniffe², G. da Gente², R. Hirose⁴, G. Roll⁴, C. E. Freise⁴, J. P. Roberts⁴
¹Immunogenetics and Transplantation Laboratory (ITL), San Francisco, CA, ²Department of Surgery, Immunogenetics and Transplantation Laboratory (ITL), San Francisco, CA, ³Department of Pathology, University of California San Francisco, San Francisco, CA, ⁴Department of Surgery, University of California San Francisco, San Francisco, CA, ⁵Department of Medicine, University of California San Francisco, San Francisco, CA
*Purpose: Over 50% of kidney transplant (Ktx) candidates with 100% CPRA display HLA-DP antibodies, which impair the chances of finding a compatible deceased donor (DD)…
2019 American Transplant Congress
Non-HLA Antibodies against Structural and Non-Structural Target in C4d Negative Antibody Mediated Rejections after Renal Transplantation
S. Kanangat¹, I. Kurbegovic-Skaljic², D. Cimbaluk², M. Oppermann², S. Jensik³, E. Hollinger³, O. Olaitan⁴, R. DeCresce²
¹Tumor Immunology, NIH/NCI Bethesda MD,USA, Bethesda, MD, ²Pathology, Rush University Medical Center, Chicago, IL, ³Surgery, Rush University Medical Center, Chicago, IL, ⁴Tumor Immunology, Rush University Medical Center, Chicago, IL
*Purpose: According to the latest Banff’s criteria approved in 2003, antibody mediated rejections following renal transplantation are divided into 2 types namely C4d + and…
2019 American Transplant Congress
Reduction of Circulating DSA: Does It Affect Histology?
M. Gupta¹, E. Edusei¹, S. Tsai², M. Magruder², J. Lee¹, J. Lee¹, C. Hartono¹, T. Muthukumar¹, M. Everly³, D. Dadhania¹
¹Nephrology, New York Presbyterian Weill Cornell, New York, NY, ²New York Presbyterian Weill Cornell, New York, NY, ³Terasaki Research Institute, Los Angeles, CA
*Purpose: De novo donor specific antibodies (dnDSA) are reported in 13-30% of kidney transplant recipients. dnDSA has been associated with antibody mediated rejection (AMR) and…
2019 American Transplant Congress
Daratumumab for Treatment of Antibody-Mediated Rejection in a Kidney Transplant Recipient
S. C. Jordan¹, R. Vescio², M. Toyoda³, N. Ammerman¹, E. Huang¹, A. Peng¹, S. Sethi¹, R. Najjar¹, K. Lim¹, A. Vo¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Ctr, Los Angeles, CA, ²Cedars-Sinai Medical Ctr, Los Angeles, CA, ³Transplant Immunology Lab, Cedars-Sinai Medical Ctr, Los Angeles, CA
*Purpose: Antibody-Mediated Rejection (ABMR) is a severe form of rejection mediated by B-cells, plasma cells and antibodies. The consequences to the patients with ABMR are…
2019 American Transplant Congress
Solving Target Recognition and Activation Mediated by Non-HLA Agonistic Antibodies Targeting ETAR
A. Philippe¹, R. Catar¹, P. Scheerer², M. Szczepek², D. Dragun¹
¹Nephrology and Medical Intensive Care, Charité Universitätsmedizin Berlin, Berlin, Germany, ²Institute of Medical Physics and Biophysics, Charité Universitätsmedizin Berlin, Berlin, Germany
*Purpose: Endothelin-1 type A receptor (ETAR) exhibits multiligand binding abilities and may signal upon natural ligand Endothelin-1 (ET-1) and non-HLA ETAR-agonistic IgG (ETAR-IgG)-mediated stimulation similar…